Advertisement

Payer

Novel therapeutics are innovative pharmaceutical and biotech products that improve clinical outcomes, but payers face many challenges when deciding whether to cover them, according to a new report from the Center for Connected Medicine at Pittsburgh-based UPMC and KLAS Research.

Advertisement
Advertisement